Back in Europe, German software giant SAP posted a 58% year-on-year operating profit jump in constant currency for the first ...

and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed ...

The health-care industry group of the S&P 500 has fought back to near the flat line for the year to date. Orchestra BioMed Holdings shares initially surged after the maker of medical devices said a ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

European stock markets slightly rose on Tuesday, propelled by gains in financials and L'Oreal shares. Uncertainty persisted ...

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

European shares ended slightly higher on Tuesday on the back of rising financials and post-earnings gains in L'Oreal, though ...

Novo Nordisk's booming obesity drugs & diabetes portfolio make it a top growth play. Click here to read an analysis of NVO ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...